A detailed history of Gsa Capital Partners LLP transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 67,546 shares of GOSS stock, worth $52,010. This represents 0.01% of its overall portfolio holdings.

Number of Shares
67,546
Holding current value
$52,010
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$0.79 - $1.25 $53,361 - $84,432
67,546 New
67,546 $67,000
Q2 2023

Aug 14, 2023

BUY
$0.98 - $1.53 $450,159 - $702,799
459,346 Added 1803.05%
484,822 $581,000
Q1 2023

May 12, 2023

SELL
$0.96 - $2.92 $96,980 - $294,981
-101,021 Reduced 79.86%
25,476 $32,000
Q4 2022

Feb 13, 2023

BUY
$1.74 - $12.87 $148,296 - $1.1 Million
85,228 Added 206.52%
126,497 $274,000
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $140,212 - $289,371
19,447 Added 89.12%
41,269 $494,000
Q2 2022

Aug 09, 2022

BUY
$5.97 - $9.97 $12,626 - $21,086
2,115 Added 10.73%
21,822 $183,000
Q1 2022

May 11, 2022

BUY
$8.44 - $12.49 $166,327 - $246,140
19,707 New
19,707 $171,000
Q4 2021

Feb 14, 2022

SELL
$10.12 - $14.07 $107,049 - $148,832
-10,578 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$7.25 - $13.23 $76,690 - $139,946
10,578 New
10,578 $133,000
Q2 2021

Aug 05, 2021

SELL
$8.0 - $9.75 $308,048 - $375,433
-38,506 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$8.63 - $10.94 $332,306 - $421,255
38,506 New
38,506 $356,000
Q4 2020

Feb 03, 2021

SELL
$8.3 - $13.59 $526,726 - $862,434
-63,461 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$11.3 - $14.75 $558,762 - $729,358
49,448 Added 352.87%
63,461 $788,000
Q2 2020

Aug 11, 2020

SELL
$9.52 - $15.98 $210,277 - $352,966
-22,088 Reduced 61.18%
14,013 $182,000
Q1 2020

May 12, 2020

BUY
$8.0 - $15.48 $288,808 - $558,843
36,101 New
36,101 $366,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $72.3M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.